Massimo Cristofanilli, MD, on Clinical Implications of Treatment With Palbociclib Plus Fulvestrant for Breast Cancer

Posted: Monday, June 7, 2021

Massimo Cristofanilli, MD, of the Feinberg School of Medicine at Northwestern University, talks about why the phase III PALOMA-3 trial provides key evidence for clinicians prescribing palbociclib plus fulvestrant for women with advanced hormone receptor–positive, HER2-negative breast cancer. He also addresses toxicities associated with this combination and how to manage them.